The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
Authors
Keywords
-
Journal
Biomarker Research
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-03-07
DOI
10.1186/s40364-022-00355-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
- (2022) Lisa Derosa et al. NATURE MEDICINE
- Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
- (2022) Shuhang Wang et al. npj Precision Oncology
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- (2021) Tina Cascone et al. NATURE MEDICINE
- Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
- (2021) Diwakar Davar et al. SCIENCE
- Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes
- (2021) Stefan C. Dentro et al. CELL
- 27P The association between gut microbiome and response to checkpoint inhibitor therapy in non-small cell lung cancer
- (2021) J. Moon et al. Journal of Thoracic Oncology
- 1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial
- (2021) M. Wislez et al. ANNALS OF ONCOLOGY
- 1160P Efficacy and biomarker identification of neoadjuvant chemo-immunotherapy in potentially resectable non-small cell lung cancer
- (2021) Y. Zhang et al. ANNALS OF ONCOLOGY
- Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
- (2021) A. Cortellini et al. ANNALS OF ONCOLOGY
- 997P STK11 and KEAP1 mutational status and their impact in survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: Meta-analyses of clinical trials and cohort studies
- (2021) G. de Castro Jr. et al. ANNALS OF ONCOLOGY
- 1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C
- (2021) R. Dziadziuszko et al. ANNALS OF ONCOLOGY
- LBA68 Clinical value of pre-treatment T-cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy
- (2021) A. Abed et al. ANNALS OF ONCOLOGY
- 1294P 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC
- (2021) F.G. Dall'Olio et al. ANNALS OF ONCOLOGY
- LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
- (2021) E. Felip et al. ANNALS OF ONCOLOGY
- 1279P The prognostic value of chemotherapy-induced neutropenia (CIN) in patients with advanced non-small cell lung cancer (NSCLC) in the era of chemoimmunotherapy (CIT)
- (2021) A. Meisel et al. ANNALS OF ONCOLOGY
- Driver mutations to predict for poorer outcomes in non-small cell lung cancer patients treated with concurrent chemoradiation and consolidation durvalumab.
- (2021) Yufei Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Age affects the efficacy of immune checkpoint inhibitors in patients with advanced cancer.
- (2021) Yongjie Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade.
- (2021) Biagio Ricciuti et al. JOURNAL OF CLINICAL ONCOLOGY
- Investigating the various predictive values of POLE/POLD1 mutations for response to immune checkpoint inhibitors (ICIs) in different solid tumors.
- (2021) Yanling Niu et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC).
- (2021) Hyojin Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of STK11 mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma cohort.
- (2021) Rebecca Suk Heist et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.
- (2021) Shengli Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.
- (2021) Jeanne Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.
- (2021) Joao Victor Machado Alessi et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic effect of DDR pathway with different functional annotations for immune checkpoint inhibitor.
- (2021) Wei Nie et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.
- (2021) Biagio Ricciuti et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal next-generation sequencing (NGS) panel for estimating tumor mutation burden (TMB) and its clinical implication for non-small cell lung cancer (NSCLC).
- (2021) Takaya Ikeda et al. JOURNAL OF CLINICAL ONCOLOGY
- The predictive values of loss-of-function variants in histone methyltransferases for response to immune checkpoint inhibitors in solid tumors.
- (2021) Naixin Liang et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential monitoring of PD-L1 on circulating stromal cells in blood predicts PFS in NSCLC patients undergoing immunotherapy after definitive chemoradiation.
- (2021) Daniel L Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Predicting response to pembrolizumab in non-small cell lung cancer, by analyzing the spatial arrangement of tumor infiltrating lymphocytes using deep learning.
- (2021) Efrat Ofek et al. JOURNAL OF CLINICAL ONCOLOGY
- Pseudoprogression and cancer immunotherapy: A seven year retrospective study of rate, temporal course, and predictive markers in an Irish tertiary referral center.
- (2021) Kate McKendry et al. JOURNAL OF CLINICAL ONCOLOGY
- Awareness and utilization of tumor mutation burden (TMB) as a biomarker for administration of immuno-oncology (I-O) therapeutics by practicing community oncologists in the United States (U.S.).
- (2021) Kristin M. Zimmerman Savill et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC
- (2021) Masayuki Shirasawa et al. Journal of Thoracic Oncology
- TIM-3 restrains anti-tumour immunity by regulating inflammasome activation
- (2021) Karen O. Dixon et al. NATURE
- MA03.05 DNA Damage Response (DDR) Gene Mutations and Correlation With Immunotherapy Response in NSCLC Patients
- (2021) J. Liu et al. Journal of Thoracic Oncology
- P57.13 Correlation of TP53/KMT2C co-mutation and Tumor Microenvironment in Lung Cancer
- (2021) X. Zhang et al. Journal of Thoracic Oncology
- MA09.01 LCMC3: Immune Cell Subtypes Predict Nodal Status and Pathologic Response After Neoadjuvant Atezolizumab in Resectable NSCLC
- (2021) F. Oezkan et al. Journal of Thoracic Oncology
- MA09.03 Peripheral CD8+ T Cells Predicts Immune-Related Adverse Events and Survival in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy
- (2021) K. Wu et al. Journal of Thoracic Oncology
- P57.02 Integration of Systemic / Tumor PD-L1 as a Predictive Biomarker of Clinical Outcome in Advanced NSCLC Patients Treated With Anti-PD-(L)1 Agents
- (2021) G. Anguera Palacios et al. Journal of Thoracic Oncology
- MA09.05 PD1-Positive Tertiary Lymphoid Structure as a Predictive Factor of Durable Clinical Effect in Immunotherapy for NSCLC
- (2021) Y. Matsumura et al. Journal of Thoracic Oncology
- MA07.02 Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150
- (2021) Z.J. Assaf et al. Journal of Thoracic Oncology
- P57.03 Cellular Engagement and Interaction in the Tumor Microenvironment (TME) Predicts Response to ICI in Metastatic NSCLC
- (2021) A. Qin et al. Journal of Thoracic Oncology
- P57.05 Low Variant Allele Frequency of TP53 as a Biomarker for PD-1/PD-L1 Inhibitors in Lung Adenocarcinoma
- (2021) S. Wang et al. Journal of Thoracic Oncology
- OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy
- (2021) A. Romero et al. Journal of Thoracic Oncology
- P44.01 Clinical Predictive Markers of Response to Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2021) R. Rhone et al. Journal of Thoracic Oncology
- FP12.01 PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC
- (2021) S. Lau et al. Journal of Thoracic Oncology
- FP12.02 Pembrolizumab as a Monotherapy or in Combination With Platinum-Based Chemotherapy in NSCLC: Correlation With Blood Biomarkers
- (2021) L. Holtzman et al. Journal of Thoracic Oncology
- P57.07 The Scottish Immunotherapy Prognostic Score (SIPS) Predicts Response to First-Line Pembrolizumab for Metastatic Non-Small Cell Lung Cancer
- (2021) M. Stares et al. Journal of Thoracic Oncology
- FP04.02 RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
- (2021) J. Wang et al. Journal of Thoracic Oncology
- New predictors for immunotherapy responses sharpen our view of the tumour microenvironment
- (2020) Tullia C. Bruno NATURE
- B cells are associated with survival and immunotherapy response in sarcoma
- (2020) Florent Petitprez et al. NATURE
- Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer
- (2020) Biagio Ricciuti et al. CLINICAL CANCER RESEARCH
- A Modified Algorithm Adjusting Both High and Minor Allele Frequency Mutation to Redefine Blood-Based Tumor Mutational Burden (bTMB) for Optimal Prediction of Clinical Benefits From Immune Checkpoint Inhibitor Therapy
- (2020) Zhichao Liu et al. Journal of Thoracic Oncology
- Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
- (2020) Maud Mayoux et al. Science Translational Medicine
- Tim-3 finds its place in the cancer immunotherapy landscape
- (2020) Nandini Acharya et al. Journal for ImmunoTherapy of Cancer
- 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
- (2020) B. Besse et al. ANNALS OF ONCOLOGY
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
- (2019) Zhibo Zhang et al. Cancer Medicine
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients
- (2019) Yueping Jin et al. Journal of Thoracic Oncology
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
- (2019) Heng-Huan Lee et al. CANCER CELL
- UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
- (2019) Yochai Wolf et al. CELL
- Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer
- (2019) Ilaria Alborelli et al. JOURNAL OF PATHOLOGY
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1
- (2019) Joo Sang Lee et al. JAMA Oncology
- Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy
- (2019) Yuting Liu et al. CLINICAL CANCER RESEARCH
- Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors
- (2019) Fumihiro Shoji et al. LUNG CANCER
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
- (2018) Ludmila Danilova et al. Cancer Immunology Research
- Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients
- (2018) Ari Vanderwalde et al. Cancer Medicine
- Soluble immune checkpoints in cancer: production, function and biological significance
- (2018) Daqian Gu et al. Journal for ImmunoTherapy of Cancer
- TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
- (2017) Wenwen Du et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
- (2017) Yusuke Okuma et al. LUNG CANCER
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
- (2017) Sean P. Arlauckas et al. Science Translational Medicine
- Neutrophils dominate the immune cell composition in non-small cell lung cancer
- (2017) Julia Kargl et al. Nature Communications
- Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma
- (2017) Young Kwang Chae et al. Oncotarget
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer
- (2016) Dong-Qiang Zeng et al. Oncotarget
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- A dendritic-cell brake on antitumour immunity
- (2015) Miriam Merad et al. NATURE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis
- (2015) Jiao Zhang et al. Scientific Reports
- Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer
- (2014) Claire Germain et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Microenvironmental regulation of tumor progression and metastasis
- (2013) Daniela F Quail et al. NATURE MEDICINE
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
- (2013) N. Iida et al. SCIENCE
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
- (2013) S. Viaud et al. SCIENCE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search